🔗 Share this article

A shadow market for unlicensed slimming drugs is being driven by social media fitness personalities and vendors on messaging platforms, according to new investigations.

Investigational Treatment Acquiring Traction Online

The experimental drug, which remains in clinical trials, is being advertised by social media influencers for its alleged weight-reducing effects. Followers are encouraged to contact these profiles privately for supplier links, while also obtaining discount codes.

Thriving Commerce on Social Networks

Additionally, a flourishing market exists on Telegram, where communities with thousands of members share comparison photos, injection guides and assertions of next-day UK delivery. Sellers promote the drug there before redirecting customers to WhatsApp for transactions.

Understanding Retatrutide

This medication is an experimental injectable created by American pharmaceutical company Eli Lilly. The treatment targets three gut hormones – GLP-1, glucose-dependent insulinotropic polypeptide and pancreatic hormone. Early trials indicate it could assist patients reduce up to a quarter of their total weight. Referred to as the “triple G”, the substance is being promoted digitally as the successor to Ozempic.

Healthcare Experts Voice Concerns

Nevertheless, physicians and pharmacists have cautions that the distribution of what remains an unapproved drug in the United Kingdom is worrisome and could lead to users injecting products of uncertain source.

Several experts stated the demand for retatrutide could be linked to the increasing price of licensed weight loss treatments such as Mounjaro.

Legal Status and Implementation

Selling the unapproved drug on social media or messaging apps is illegal in the United Kingdom, as it is an unlicensed drug that cannot be promoted or distributed for human use under the Human Medicines Regulations 2012.

Several influencers try to circumvent the regulations by referring to the drug as a “research chemical” or citing it as “not for human consumption”. Retatrutide is not a controlled substance, but promotion and distribution can still violate medicines, advertising, and customer regulations, risking penalties, legal action or prison.

Service Reaction and Content Elimination

Based on the social media company, the platform has taken down problematic material and prohibited related keywords and query recommendations. The organization stated it was dedicated to maintaining the platform secure and allocating resources in enhancing compliance measures.

Digital Marketplace Operations

Investigations also found communities with up to nine thousand members selling retatrutide using the platform's built-in search feature, which functions like a online catalog. Entering “retatrutide” immediately brings up groups with thousands of users, filled with images of weight loss, glowing testimonials and step-by-step instructions for mixing or administering at residence.

After moments of joining one group, a seller shared contact information, where most purchases take place. The vendor provided an instruction manual and guaranteed delivery within two days. When asked whether the substance was genuine, one vendor said: “You can’t be sure.” Another shared a photo of a supposed testing documentation. Not one inquired about body mass, health issues or previous experience.

Item Details and Pricing

Inside these communities, messages display black plastic parcels with Royal Mail labels, claiming to contain new batches. One communication read: “It took eight of us to load them this morning.”

Customers can select between dry substance containers, prepared at residence with purified liquid, or ready-to-use pens usually priced at £160 for 20 milligrams. When asked how much time a injector should be used, sellers give contradictory answers ranging from a few weeks to “depends on your body”.

Service Moderation and Security Actions

A spokesperson for Telegram said it actively moderated dangerous content on its service including content that encouraged the “misuse of controlled medications”. The company noted that it removed “millions of pieces of harmful content each day”.

Healthcare Expert Warnings

“People are injecting substances they cannot confirm. Although the research behind this drug is sound, these digital products may not contain what they advertise,” said a pharmacy expert, the head of pharmaceutical services at Chemist4U.

A medical professional of Asda Online Doctor linked the increase in interest to recent cost increases for approved weight-loss drugs such as Mounjaro. “With prices rising, individuals are turning to online platforms. But counterfeit injections are highly risky. You cannot know what’s inside or whether the conditions they were produced in was sterile,” she explained.

Her staff has previously encountered patients injured by personal administration from unverified suppliers. “We understand the disappointment, but purchasing from Telegram or WhatsApp is gambling with your well-being,” stated the doctor. “These materials could be impure or incorrectly dosed.”

Manufacturer Position

A representative from the pharmaceutical company said the substance was in third stage clinical trials and had not been evaluated or authorized by any government authority globally. “Consequently at this time no one can sell [it] for personal consumption,” they said, adding that any product “misleadingly claiming itself as a Lilly experimental product not yet authorized … may expose users to possibly serious medical dangers”.